In patients with CML who are receiving 1st line TKI with good molecular response, are you continuing therapy or switching to asciminib based on the ASC4FIRST data?
Community PollStarted
Does the ASC4FIRST data change how you would manage a CML patient who is already on 1L TKI with good molecular response?
81 physicians have voted
Join Mednetto vote and see how they answered.
2 Answers
Mednet Member
Hematology · Memorial Sloan Kettering Cancer Center
Answered on
For a CML patient with optimal response and excellent tolerability to their current TKI, there should not be impetus to switch to asciminib. For patients with less than optimal response, diminished quality of life, and in certain settings of adverse effects from current therapy, consideration of TKI...
Join for free or sign in to see the full answer
Mednet Member
Hematology · University of Washington School of Medicine
Answered on
If patients are responding, I generally do not switch unless tolerance is an issue and dose reduction is not feasible/recommended.
Join for free or sign in to see the full answer